Public Release: 

Novel blood test predicts kidney cancer risk and survival five years prior to diagnosis

Concentrations of KIM-1 in the blood predicted kidney cancer diagnosis and were associated with poorer survival

Brigham and Women's Hospital

A critical biomarker of kidney disease may help predict clear cell kidney cancer - the most common form of kidney cancer - years before clinical diagnosis. Kidney-injury-molecule-1 (KIM-1) can be detected in the urine and blood and is generally present at low levels in healthy individuals. Prior research by leaders at Brigham and Women's Hospital has shown that KIM-1 is an important and highly predictive marker for kidney injury. In a new study published in Clinical Cancer Research, BWH investigators, along with colleagues from Beth-Israel Deaconess Medical Center, Imperial College, London, and the International Agency for Research on Cancer, explore whether a blood test can detect higher concentrations of KIM-1 in patients who will go on to develop kidney cancer up to five years later. Their results show that KIM-1 substantially helped distinguish between those who went on to develop kidney cancer from those who did not.

"Early detection of kidney cancer can be lifesaving. We can cure kidney cancer when we detect it at an early stage, but patients with advanced kidney cancer have a very high death rate," said Venkata Sabbisetti, PhD, a research faculty member in the BWH Renal Division and a co-author of the study. However, kidney cancer is asymptomatic and many patients present with advanced kidney cancer at the time of diagnosis. Our results suggest that with further refinement, KIM-1 has the potential to identify patients with early, curable kidney cancer."

Sabbisetti and colleagues measured KIM-1 concentrations in samples from patients enrolled in the European Prospective Investigation into Cancer and nutrition (EPIC). The team compared KIM-1 levels from 190 participants who went on to develop RCC within the next five years to 190 matched participants (same age, body mass index, smoking status, etc.) who didn't develop kidney cancer. Higher levels of KIM-1 are associated with higher risk of development kidney cancer and poorer survival.

The team reported that adding KIM-1 to a model for predicting kidney cancer risk approximately doubled the accuracy of that model. KIM-1 was substantially more sensitive for kidney cancer detection than prostate specific antigen is for prostate cancer. However, given the rarity of kidney cancer, plasma KIM-1 alone may not to be suited for early detection in the general population.

"We envision that KIM-1 will be useful in settings where the risk of kidney cancer is higher, such as patients undergoing abdominal CT scanning, where KIM-1 could be used to stratify risk of RCC," the authors wrote. "This will be particularly important given the rise of routine CT scans and the strong association between number of CT scans and number of nephrectomies performed at the regional level in the U.S., indicating a substantial burden of overdiagnosis."

###

Funding for this work was provided by the National Institutes of Health (R01 CA196996 and P50 CA101942-12) and a Cancer Research UK Population Research Fellowship.

Paper cited: Scelo G et al. "KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case-control study." Clinical Cancer Research DOI: 10.1158/1078-0432.CCR-18-1496

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.